Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q1 EPS of $0.68, $0.34 better than the analyst estimate of $0.34. Revenue for the quarter came in at $141.4 million versus the consensus estimate of $131.54 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2025 revenue of $545-565 million, versus the consensus of $557.2 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.